Welcome to our dedicated page for Protagonist Therapeutics SEC filings (Ticker: PTGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Protagonist Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Protagonist Therapeutics's regulatory disclosures and financial reporting.
PTGX-related transaction notice: A broker-dealer submission lists the proposed sale and related exercise of 9,000 shares. The filing records a 10b5-1 sale of 9,000 shares on 05/29/2026 producing $896,730.30 and an exercise of stock options for 9,000 shares on 06/10/2026 with cash payment.
Protagonist Therapeutics director William D. Waddill exercised stock options and sold shares in a coordinated transaction. He exercised 9,000 shares of Common Stock at $11.80 per share, then sold 9,000 shares in an open-market sale at $99.64 per share.
After these transactions, he directly holds 7,825 shares of Common Stock and 3,000 stock options remain outstanding, with the options expiring on June 6, 2029. The filing notes the trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026, indicating they were scheduled in advance.
Protagonist Therapeutics President and CEO Dinesh V. Patel reported an exercise-and-sale transaction involving 75,000 shares of common stock. On May 12, 2026, he exercised stock options for 75,000 shares at $21.58 per share and sold 75,000 shares in open-market trades at a weighted average price of $100.12 per share, with individual sale prices ranging from $98.83 to $103.50. After these transactions, he directly holds 523,478 common shares. The filing notes the actions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on January 30, 2026, and that the related stock options are fully vested and expire on October 11, 2026, with 225,000 options reported as remaining outstanding.
Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel reported an exercise-and-sale transaction in company stock. He exercised stock options to acquire 75,000 shares of common stock at an exercise price of $21.58 per share, then sold 75,000 shares in an open-market transaction at a weighted average price of $100.12 per share across multiple trades ranging from $98.83 to $103.50. Following these transactions, he directly holds 523,478 shares of common stock. The exercised stock options were fully vested and are scheduled to expire on October 11, 2026.
PTGX insider sale notice: A Form 144 filing states 75,000 shares of Common Stock are to be sold on 05/12/2026 in connection with an Option Exercise for cash. The filing also reports prior sales of 54,641 shares on 03/25/2026 by Dinesh Patel.
State Street Corporation reported beneficial ownership of 3,116,804 shares of Protagonist Therapeutics Inc. The filing, a Schedule 13G, shows 4.9% of the class and discloses shared voting power of 2,956,605 and shared dispositive power of 3,116,804. The filing lists related State Street entities and was signed by a Senior Vice President on 05/12/2026.
Protagonist Therapeutics director Bryan Giraudo reported exercising stock options and selling shares of common stock. On May 7, he exercised options for 36,000 shares at exercise prices of $6.45 and $6.98 per share and sold 36,000 directly held shares at about $100.14 per share. The Bryan & Courtney Giraudo Trust sold an additional 12,000 shares that day at about $100.07 per share.
On May 8, Giraudo sold 5,130 directly held shares at $100.00 per share, and the trust sold another 6,000 shares at $100.00 per share. A footnote states these sales occurred at prices ranging from $98.69 to $104.67. After these transactions, he holds 12,695 shares of Protagonist Therapeutics common stock directly, and the trust no longer holds shares from these reported transactions. All reported stock options are shown as fully exercised, with no remaining derivative holdings in this filing.
Bryan M. Giraudo and Bryan M. & Courtney L. Giraudo reported dispositions of Common stock in a Form 144 related to PTGX. The filing shows sales on 05/07/2026: 12,000 shares by Bryan M. & Courtney L. Giraudo for $1,200,873.60 and 36,000 shares by Bryan M. Giraudo for $3,604,968.00. The record lists prior compensation issuances of 6,000 shares (12/03/2019) and 5,130 shares (01/15/2026) under issuer compensation entries.